The iPSCs generated from JMML harboring PTPN11 or CBL mutation have differential responses to the MEK inhibitors and JAK inhibitors owing to the activation of specific signaling pathways [70]. This evidence concerns the gene CBL and juvenile myelomonocytic leukemia.